In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 3.83 below Lyell Immunopharma Inc average.

Within Major Pharmaceutical Preparations industry 186 other companies have achieved higher Quick Ratio than Lyell Immunopharma Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 466 to 695.

Explain Quick Ratio?
How much Cash & cash equivalents LYEL�s has?
What are LYEL�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/LYEL/financial-strength

https://api.csimarket.com/api/v1/companies/LYEL/fundamentals

https://api.csimarket.com/api/v1/companies/LYEL/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

LYEL Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	45.15 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-44.59 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	3.83	Subscribe	Subscribe	Subscribe	Subscribe
LYEL's Total Ranking	# 695	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	16.06 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-13.23 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 187
Healthcare Sector	# 298
Overall Market	# 695

Quick Ratio Statistics
High	Average	Low
19.9	12.25	5
(Mar 31 2023)		(Dec 31 2025)

Financial Statements
Lyell Immunopharma Inc 's Current Liabilities	$ 46 Millions	Visit LYEL's Balance sheet
Lyell Immunopharma Inc 's Cash & cash equivalent	$ 177 Millions	Visit LYEL's Balance sheet
Source of LYEL's Sales		Visit LYEL's Sales by Geography

Cumulative Lyell Immunopharma Inc 's Quick Ratio

LYEL's Quick Ratio for the trailling 12 Months

LYEL Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-7.85 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-30.41 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	5.12	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3576	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	9.1 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-13.9 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to LYEL Financial Strength Comparisons >> Go to Compare LYEL Quick Ratio to its Competitors

On the trailing twelve months basis Due to increase in Current Liabilities in the Q3 2026 to $46.27 millions, cumulative Quick Ratio decreased to 5.12 below the Lyell Immunopharma Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 423 other companies have achieved higher Quick Ratio than Lyell Immunopharma Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 3510 to 3576.

Explain Quick Ratio?
How much Cash & cash equivalents LYEL�s has?
What are LYEL�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 424
Healthcare Sector	# 861
Within the Market	# 3576

trailing twelve months Quick Ratio Statistics
High	Average	Low
17.66	12.43	6.48
(Sep 30 2023)		(Jun 30 2026)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Cyclerion Therapeutics Inc	10.32	$ 456.221 Millions	$ 44.197 Millions
Lexicon Pharmaceuticals Inc	10.31	$ 183.203 Millions	$ 17.773 Millions
Adicet Bio Inc	10.28	$ 174.779 Millions	$ 16.996 Millions
An2 Therapeutics Inc	10.26	$ 64.400 Millions	$ 6.275 Millions
Pmv Pharmaceuticals Inc	10.15	$ 108.515 Millions	$ 10.689 Millions
Nuvectis Pharma inc	9.91	$ 140.707 Millions	$ 14.193 Millions
Renovorx Inc	9.76	$ 20.404 Millions	$ 2.091 Millions
Aprea Therapeutics Inc	9.52	$ 37.846 Millions	$ 3.975 Millions
Rezolute Inc	9.51	$ 89.999 Millions	$ 9.463 Millions
Opus Genetics Inc	9.05	$ 88.974 Millions	$ 9.832 Millions
Ibio inc	8.94	$ 76.654 Millions	$ 8.574 Millions
Ideaya Biosciences Inc	8.70	$ 838.541 Millions	$ 96.405 Millions
First Tracks Biotherapeutics Inc	8.60	$ 155.627 Millions	$ 18.090 Millions
Pepgen Inc	8.48	$ 104.805 Millions	$ 12.361 Millions
Ocular Therapeutix Inc	8.42	$ 530.612 Millions	$ 63.017 Millions
Bicara Therapeutics Inc	7.99	$ 442.346 Millions	$ 55.368 Millions
Arvinas Inc	7.98	$ 558.400 Millions	$ 70.000 Millions
Wave Life Sciences Ltd	7.87	$ 431.012 Millions	$ 54.760 Millions
Savara Inc	7.80	$ 129.649 Millions	$ 16.630 Millions
Rigel Pharmaceuticals Inc	7.79	$ 224.456 Millions	$ 28.806 Millions
Cytomx Therapeutics Inc	7.64	$ 347.980 Millions	$ 45.532 Millions
Atea Pharmaceuticals Inc	7.64	$ 191.199 Millions	$ 25.025 Millions
Braveheart Bio, Inc.	7.27	$ 121.291 Millions	$ 16.673 Millions
Viking Therapeutics Inc	7.17	$ 959.813 Millions	$ 133.897 Millions
Scynexis Inc	7.09	$ 47.165 Millions	$ 6.652 Millions
Lb Pharmaceuticals Inc	7.03	$ 215.075 Millions	$ 30.573 Millions
Zentalis Pharmaceuticals Inc	7.03	$ 228.893 Millions	$ 32.539 Millions
Quoin Pharmaceuticals Ltd	6.95	$ 33.184 Millions	$ 4.776 Millions
Vera Therapeutics Inc	6.89	$ 384.042 Millions	$ 55.775 Millions
Nuvation Bio Inc	6.73	$ 663.370 Millions	$ 98.559 Millions

Date modified: 2026-11-05T06:21:43+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.